Figure 1

Recurrence-free survival (A, B) and breast cancer survival (C, D) in relation to the ratio of 17β-hydroxysteroid dehydrogenase (17HSD) type 2 and type 1 mRNA expression (17HSD2/17HSD1). (A, C) oestrogen receptor-positive (ER+) patients (n=179) and (B, D) ER negative patients (n=51).